Verdict No. 3146 · Search date 2026-09-17 · Methodology v1.0
Oral single-ingredient vitamin B6 and hs-CRP changes in adults
30-Second Summary
C
Evidence Grade C · 46 · Safety caution
ChatGPT source review and self-verification · Codex technical integration
The verified evidence does not establish a reliable hs-CRP reduction from oral single B6 in adults. A randomized human study includes genuine B6-only/placebo arms and ultra-sensitive CRP, but an adjusted pure-arm change CI is unavailable. Nonsignificant factorial tests, other inflammatory markers, and PLP associations do not establish isolated B6 efficacy or an exactly zero effect.
Caution reflects peripheral-neuropathy concerns and cumulative B6 exposure across products. Unreported harms in short studies do not establish safety. The Australian TGA >50–200 mg/day pharmacist-only change is scheduled for 2027-06-01, not already effective or a Korean rule or personal dose.
What the
research showsThe verified evidence does not establish a reliable hs-CRP reduction from oral single B6 in adults. A randomized human study includes genuine B6-only/placebo arms and ultra-sensitive CRP, but an adjusted pure-arm change CI is unavailable. Nonsignificant factorial tests, other inflammatory markers, and PLP associations do not establish isolated B6 efficacy or an exactly zero effect.
research showsThe verified evidence does not establish a reliable hs-CRP reduction from oral single B6 in adults. A randomized human study includes genuine B6-only/placebo arms and ultra-sensitive CRP, but an adjusted pure-arm change CI is unavailable. Nonsignificant factorial tests, other inflammatory markers, and PLP associations do not establish isolated B6 efficacy or an exactly zero effect.
What the
ads claimNo census of product advertisements was performed; this page evaluates the isolated B6/hs-CRP question.
ads claimNo census of product advertisements was performed; this page evaluates the isolated B6/hs-CRP question.
Four separate assessment dimensions
| Effect direction and size | The core ultra-sensitive CRP pure-arm adjusted change/CI is insufficiently reported. Factorial P=.22/.90 are not pure-arm tests and do not quantify a reliable monotherapy reduction. |
|---|---|
| Evidence certainty | Low: WENBIT reanalyses are not independent replication; RA assay/comparator differences and a source-internal table conflict are kept separate. |
| Applicability | Primarily medically treated stable coronary disease; no generalization to elevated-hs-CRP selection, confirmed deficiency, healthy adults, severe renal disease, or other vitamers. |
| Safety | Caution reflects peripheral-neuropathy concerns and cumulative B6 exposure across products. Unreported harms in short studies do not establish safety. The Australian TGA >50–200 mg/day pharmacist-only change is scheduled for 2027-06-01, not already effective or a Korean rule or personal dose. |
The supplied calculator maps B/S/R1/I1/EX/B2/CX to C; zero strengths select fixed anchor46. EX(a) follows actual reconstruction attempts with an ineligible change estimand, not missing MCID alone. The score is not a success probability or official GRADE.
Useful facts when choosing a product
- Reported pyridoxine/hydrochloride forms are retained by study; no invented active-mass equivalence to PLP or other vitamers.
Chamgap Semantic Classification Code
Permanent code issued
S.vitamin-b6-hs-crp-core-pyridoxine-single.oral.hs-crp-adults-cad-ra-low-plp-separated.hs-crp-change.hs-crp-study-specific-placebo-factorial-folate-prepost-separatedSupplements and nutraceuticals > Single pyridoxine/hydrochloride; original form and active-mass limits retained > Adults; stableCAD,RA and low-PLP oral-contraceptive users kept separate > hs-CRP change > Actual placebo,factorial non-B6,common folate and pre-post separated > Oral; other or unconfirmed routes kept separate
Technical binding of unchanged ChatGPT C/46, Caution, oral single-B6/hs-CRP and actual comparator boundaries. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Vitamin B6 |
| Source or part used | Purified nutrient; botanical part not applicable |
| Formulation or processing | Single pyridoxine/hydrochloride; original form and active-mass limits retained |
| Route | Oral; other or unconfirmed routes kept separate |
| Dose | Study-specific10/40/50mg;100mg is a common-folate comparison with unconfirmed route |
| Duration | 28days/30days/6months;12weeks for common-folate comparison |
| Population | Adults; stableCAD,RA and low-PLP oral-contraceptive users kept separate |
| Effect or condition | hs-CRP change |
| Primary endpoint | Page question hs-CRP; registered-primary status separately unconfirmed |
| Comparator | Actual placebo,factorial non-B6,common folate and pre-post separated |
| Duplicate-detection key | S|vitamin-b6|purified-single-ingredient|oral|adults|hs-crp-change|actual-control-by-study |
What the research actually shows
Research question: oral single-ingredient vitamin B6 and hs-CRP change in adults, separating pure-arm placebo contrasts, factorial B6 comparisons, increments on common folate, ordinary versus high-sensitivity CRP, and PLP/diet associations.
Why this is classified as C (46)
The supplied calculator maps B/S/R1/I1/EX/B2/CX to C; zero strengths select fixed anchor46. EX(a) follows actual reconstruction attempts with an ineligible change estimand, not missing MCID alone. The score is not a success probability or official GRADE.
Counterpoint. Pure-arm adjusted CI, Huang full text/route/hs-CRP values, an official Chiang table explanation, registration histories and some cumulative exposures remain unconfirmed. This is not zero effect or absence of human studies.
Rejudgment record. same_author_completed_with_uncertainty — Supplied rubric and calculator; zero-strength C46 anchor, no override.
Stored scoring profile
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Review performed and remaining limitations
Primary full texts, tables/footnotes and PDF visuals, accessible abstracts, source-specific funding, arithmetic, axes, bilingual content and fields were self-checked. This is not external independent review.
Pure-arm adjusted CI, Huang full text/route/hs-CRP values, an official Chiang table explanation, registration histories and some cumulative exposures remain unconfirmed. This is not zero effect or absence of human studies.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Bleie 2007: WENBIT inflammation substudy | Double-blind 2×2 randomized trial with genuine B6-only and placebo arms | 90 randomized; pure B6 21/placebo 24; CRP complete cases 19/21, total 83 | Public/nonprofit grants plus free Alpharma medication and extra funding; consulting/Bevital relationships disclosed | Ultra-sensitive CRP at 6 months; geometric means in mg/L | B6-only 2.4→2.0 versus placebo 1.5→1.9; factorial P =.22, not pure-pair P; adjusted pure-arm CI unavailable | Core direct arms, limited by complete-case analysis and unverified confirmatory hs-CRP reporting |
| Ulvik 2012: selected WENBIT biomarker analysis | Post-randomization selected factorial comparison plus observational regressions | 2187 analyzed:1088 B6-factor/1099 non-B6; not 3090-person parent ITT | Article states no funding for this analysis; parent support and Bevital affiliations retained separately | Day 28 CRP, medians with 5th–95th percentiles, mg/L | 1.64→1.86 versus 1.82→1.94; within each P <.01, between-factor change P =.90 | Supportive factorial context, not pure placebo contrast or independent replication |
| Chiang 2005: rheumatoid arthritis | Double-blind randomized oral B6-only versus matching placebo | 36 recruited,33 initial assessments,28 randomized 14/14 | Taiwan NSC94-2320-B005-009, Arthritis Foundation, USDA andNCRR; manufacturers identified, donation/purchase unconfirmed | CRP at 30 days; high-sensitivity designation unconfirmed | Narrative says no effect; Table 3 prints treatment P <.0001 and baseline P =.387. Columns not silently swapped | Contextual monotherapy RCT; assay limitation and unresolved source-internal conflict |
| Huang 2010: rheumatoid arthritis | Single-blind randomized B6 increment on common folic acid, not placebo monotherapy | 35 randomized:20 B6+folate/15 folate; analyzed/attrition denominators inaccessible | Taiwan NSC-94-2320-B-040-031 verified in publisher preview; product-supply details inaccessible | hs-CRP atbaseline/week 12, distinct from IL-6/TNF and immune outcomes | hs-CRP numbers and between-group CI inaccessible; within-B6 IL-6/TNF decreases not reattributed | Relevant conditional-B6 study; route/salt and full hs-CRP results unverified |
| Rios-Avila 2015: B6-insufficient oral-contraceptive users | Uncontrolled oral B6 pre-post study; IV stable isotopes are measurement, not IVB6 | 200 screened,13 eligible,10 completed;3 withdrawals | NIHR01 DK072398 andCTSA1 UL1 RR029890; custom USP capsules, exact manufacturer unconfirmed | Fasting/fed CRP at 28 days; high-sensitivity reagent designation unconfirmed | Narrative reports unchanged CRP; numerical Supplement Table 4 unavailable; no randomized between-group effect | Nutritional/route context only; not confirmatory efficacy or placebo-controlled replication |
| Dusitanond 2005: VITATOPS inflammation substudy | Randomized combined-vitamin substudy identified at bibliographic/title level | Denominators not re-extracted from inaccessible abstract body in this work | Funding declaration not retrieved; another trial or parent disclosure not copied as substudy-specific funding | Inflammatory biomarkers, distinct from stroke incidence | Combined-strategy title verified; no unverified numerical effect imported | Excluded from isolated B6 attribution; prior stroke verdict unchanged |
Receipt — 11 References
Evidence access cutoff: 2026-09-17. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis
Oral monotherapy RCT; ordinary CRP with unconfirmed high-sensitivity designation; source-internal CRP significance conflict. Oral monotherapy RCT; ordinary CRP with unconfirmed high-sensitivity designation; source-internal CRP significance conflict.
checkedVitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis
Explicit hs-CRP measured; randomized B6 increment on shared folic acid, not placebo-controlled monotherapy; route/salt unconfirmed in accessible text. Explicit hs-CRP measured; randomized B6 increment on shared folic acid, not placebo-controlled monotherapy; route/salt unconfirmed in accessible text.
checkedHomocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease
Core oral pure-B6 versus placebo arms with explicitly ultra-sensitive CRP; factorial tests kept separate. Core oral pure-B6 versus placebo arms with explicitly ultra-sensitive CRP; factorial tests kept separate.
checkedAssociation of plasma B-6 vitamers with systemic markers of inflammation before and after pyridoxine treatment in patients with stable angina pectoris
Same parent trial; selected 28-day factorial biomarker analysis and associations, not independent replication or pure-arm contrast. Same parent trial; selected 28-day factorial biomarker analysis and associations, not independent replication or pure-arm contrast.
checkedEvidence for increased catabolism of vitamin B-6 during systemic inflammation
Same-WENBIT mechanistic/association follow-up; no additional randomized cohort counted. Same-WENBIT mechanistic/association follow-up; no additional randomized cohort counted.
checkedPyridoxine supplementation does not alter in vivo kinetics of one-carbon metabolism but modifies patterns of one-carbon and tryptophan metabolites in vitamin B-6-insufficient oral contraceptive users
Uncontrolled oral B6 before-after study; CRP assay not explicitly high-sensitivity. Stable isotope IV infusions are measurement, not IV B6. Uncontrolled oral B6 before-after study; CRP assay not explicitly high-sensitivity. Stable isotope IV infusions are measurement, not IV B6.
checkedEffect of vitamin B6 and antihelicobacter pylori on prognosis and serum levels of inflammation mediators in patients with acute coronary...
Potentially relevant lead, not used as efficacy evidence. Route, randomization, comparator, hs-CRP data and combination separability unconfirmed. Potentially relevant lead, not used as efficacy evidence. Route, randomization, comparator, hs-CRP data and combination separability unconfirmed.
checkedHomocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial
Combined-vitamin inflammation substudy; excluded from isolated B6 effect. No stroke efficacy re-review. Combined-vitamin inflammation substudy; excluded from isolated B6 effect. No stroke efficacy re-review.
checkedMedicines containing vitamin B6 (pyridoxine, pyridoxal or pyridoxamine)
Reused safety map updated against official page; not efficacy evidence. Reused safety map updated against official page; not efficacy evidence.
checkedVitamin B6: Fact Sheet for Health Professionals
Safety/form map reused; EFSA/US limits are not doses recommended for hs-CRP. Safety/form map reused; EFSA/US limits are not doses recommended for hs-CRP.
checkedVitamin B6 Reduces Nitric Oxide ... Post-Laparotomy ... Wistar Rats
Nonhuman intramuscular rat model; excluded from oral adult hs-CRP efficacy. Nonhuman intramuscular rat model; excluded from oral adult hs-CRP efficacy.
checkedTASK-1030 hs-CRP question only; previously completed manuscripts/grades not reassessed.
Technical integration by: Codex · Evidence date: 2026-09-17 · Corrections: none
Technical integration by: Codex · Evidence date: 2026-09-17 · Corrections: none
Cite this verdict
[Chamgap] Oral single-ingredient vitamin B6 and hs-CRP changes in adults — Evidence Grade C·46. 11 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/oral-single-vitamin-b6-adults-hs-crp-change/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.